Escalon: Expansion Efforts Impact Gross Margins
Escalon Medical managed solid revenue growth its first fiscal quarter of 2009. The company reported quarterly revenues of $8.7 million, compared with $6.9 million in […]
[Video Profile] Interview with Eric Le Royer, CEO of EndoSense SA
Endosense is developing a catheter ablation treatment for cardiac rhythm disorders, including atrial fibrillation (AF). AF is the most common cardiac rhythm disorder today, affecting […]
Endologix Rejects Elliott Associates Buyout Bid
Regular Sentinel readers know I’m a fan of Endologix. The developer of a minimally invasive treatment for abdominal aortic aneurysms has had a slate of […]
Endocare and Galil Medical to Merge
Only months after Healthtronics withdrew its offer to acquire Endocare for $2.28 per share, Endocare and privately held Galil Medical have agreed to merge. The […]
Abiomed: Record Revenue Driven by Impella
In June, Abiomed got the green light from the FDA to market its Impella 2.5 CAD, a minimally invasive ventricular assist device. At the time, […]
[Video Interview] Richard Taney, President & CEO of Delcath Systems
One of the central problems in using chemotherapy to treat cancer is its harmful effect on organ health. Lower dosages of the drug are often […]
Cyberkinetics Neurotechnology Nearing Paralysis
In a recent filing, Cyberkinetics Neurotechnology said it only had enough cash to last 30 days. If negotiations fail with its secured creditor, GE Capital, […]
AngioDynamics Integrates Diomed’s EVLT
Having acquired onetime rival Diomed for a song, AngioDynamics has launched a new varicose vein therapy brand, VenaCure EVLT. The new brand combines AngioDynamics’ VenaCure […]
Symphony Medical Raises $10 Million
Symphony Medical, a privately-held company developing novel biocompatible polymer therapies to treat chronic heart failure and atrial fibrillation has raised $10 million in a Series […]
CryoLife: EPS Increases, Revenues Up 21%
Revenues at CryoLife rose 21% to $26.8 million in the third quarter of 2008. Net income was $3.6 million, or $0.13 per share, compared to […]